Pharma cold chain logistics companies should be compared by the work they actually control: product and lane scope, storage and transport conditions, packaging responsibility, monitoring, handoffs, exception response and documented quality evidence. A familiar company name or a certification does not prove that a specific product, packout and route are suitable. Approval should be based on the exact service configuration and the evidence behind it.
This guide explains the provider landscape and the capability checks needed before shortlisting. It does not rank companies or replace a product-specific quality agreement, lane assessment or qualification study. For the full procurement sequence, use the separate pharma logistics partner selection guide.
1. Define the shipment before comparing companies
Start with a written shipment profile. A provider cannot demonstrate fit until the shipper defines what must be protected and where responsibility begins and ends. “Pharmaceutical cold chain” can mean routine finished-dose distribution, clinical-trial supply, biologic samples, vaccines, cell and gene therapies or another controlled product. Those flows do not create the same operational or evidence burden.
| Shipment input | What to define | Why it changes the provider decision |
|---|---|---|
| Product condition | Approved storage and transport conditions, allowable excursions and any sensitivity to freezing, shock, light or orientation | Determines handling, packaging, monitoring and escalation requirements |
| Payload profile | Minimum and maximum quantity, dimensions, thermal mass, primary container and value or scarcity | Changes packout, capacity, security and recovery planning |
| Lane | Origin, destination, modes, hubs, customs, dwell points, season and credible delay | Defines the actual chain of custody and exposure challenge |
| Service boundary | Pickup, storage, packing, replenishment, transport, delivery, unpacking, returns and data review | Shows which party owns each task and handoff |
| Evidence level | Required procedures, qualifications, calibration, training, audit access and records | Separates a sales description from an approvable service |
| Exception rule | Alarm thresholds, notification times, decision authority, quarantine and investigation process | Determines whether an excursion can be contained and assessed |
The product owner must set the acceptable conditions; there is no universal pharmaceutical temperature range. Use the Route Risk Checker to organize lane and delay inputs before requesting proposals.
2. Separate the provider types
Many searches treat every participant as a “logistics company,” but the operating models are different. One organization may combine several roles, while another may subcontract parts of the journey. The comparison should therefore be role by role, not logo by logo.
| Provider type | Typical role | Capability that needs separate proof |
|---|---|---|
| Integrated logistics provider | Coordinates transport, warehousing, freight forwarding and network control across multiple modes or regions | Exact site, lane, subcontractor and temperature-control scope |
| Specialty pharma courier | Handles urgent, high-value, clinical-trial or patient-specific shipments with tighter chain-of-custody controls | Coverage, after-hours escalation, custody records and contingency execution |
| Clinical-trial logistics provider | Supports depot activity, kit distribution, returns, comparator products and site or patient delivery | Protocol-specific workflows, blinding controls, inventory accuracy and country coverage |
| Advanced-therapy or cryogenic specialist | Supports time-critical cell, gene, tissue or cryogenic materials | Cryogenic equipment, identity and custody controls, replenishment, recovery and trained handling |
| Cold storage or 3PL operator | Stores, picks, packs and distributes controlled products from qualified facilities | Facility mapping, alarms, backup systems, segregation, inventory controls and release status |
| Packaging system provider | Supplies insulated shippers, coolant systems, packout instructions or testing support | Complete-system qualification for the defined payload and route; not transport execution by default |
| Monitoring provider | Supplies loggers, real-time devices, platforms, calibration or data services | Sensor accuracy, calibration, placement, connectivity, data ownership and alarm workflow |
A packaging supplier, monitoring vendor and transporter can all be essential, but their responsibilities are not interchangeable. The pharmaceutical products and service-provider guide maps the broader supplier ecosystem.
3. Match the operating model to the use case
Routine commercial distribution often favors repeatable scheduled lanes, qualified facilities, scalable capacity and consistent data flow. Clinical-trial logistics may add depot coordination, protocol changes, returns, blinded material, country import requirements and direct delivery to research sites or patients. Advanced therapies can introduce very short decision windows, strict identity and custody controls, cryogenic systems and recovery procedures.
The right model can be a lead logistics provider with approved subcontractors, a specialist controlling the complete shipment, or a coordinated set of providers under the shipper’s quality system. The decision should reflect the risk and evidence required, not a preference for one organizational shape.
Where several providers participate, name the party accountable for end-to-end coordination. A collection of individually capable vendors can still fail if no one owns handoffs, data consolidation or exception decisions.
4. Map every lane, handoff and outsourced activity
Create a lane map from packing start to final receipt, including collection, airport or road terminals, controlled storage, customs, last-mile delivery and any returns. For each node, record the legal entity, facility, transport mode, expected dwell, environmental control, monitoring method and escalation contact.
The EU Good Distribution Practice guidelines place outsourced activities within the quality system and require responsibilities to be defined and controlled. In the United States, 21 CFR 211.142 addresses written warehousing procedures and appropriate storage, while 21 CFR 211.150 addresses written distribution procedures and traceability. Apply the rules governing the product and jurisdictions involved; these sources are not interchangeable global approvals.
Ask whether any lane, site, carrier or agent can change without prior notice. If subcontracting is permitted, define approval, oversight, data access and change-control requirements before the first shipment.
5. Verify packaging and monitoring boundaries
Do not assume the logistics provider owns the packaging design. Determine who selects the shipper, conditions coolant, assembles the packout, verifies component identity, places the monitor and releases the package. If a provider supplies a prequalified solution, review the payload limits, loading pattern, conditioning method, thermal profile, test report and any route assumptions behind that claim.
Helpful decision tools
Check the details before you choose packaging
These quick tools can help you compare route risk, sizing needs, coolant choices, and packaging details before you request a quote.
Packaging Selector
Compare insulated packaging options by product, route, and temperature need.
Find packagingIce Pack Calculator
Estimate gel ice pack quantity for chilled shipments and practical route planning.
Estimate ice packsBox Liner & Pallet Cover Sizing
Check box liner and pallet cover sizing logic for insulated packaging projects.
Estimate sizing
Monitoring also requires a complete workflow. A logger does not protect a shipment by itself. Define device accuracy and calibration, placement, start and stop steps, alarm routing, connectivity gaps, data access, review responsibility and the action taken when a limit is exceeded. The pharma cold-chain monitoring guide covers those controls in more detail.
The WHO distribution guidance collection includes resources on route profiling, shipping-container qualification, monitoring and transport. Use the documents applicable to the product and governing authority.
6. Compare evidence, not marketing labels
| Capability area | Evidence to request | What a weak answer looks like |
|---|---|---|
| Quality system | Applicable licences or certifications, audit scope, deviations, CAPA, change control and management responsibility | A certificate without the covered legal entity, site, service or expiry information |
| Facility and equipment | Qualification or mapping summary, calibration, maintenance, alarm tests, backup power and contingency records | “Temperature controlled” with no defined zone, limits or evidence |
| Lane capability | Lane map, route-risk assessment, seasonal exposure, dwell assumptions, customs plan and alternate routes | A global network map that does not identify the actual lane |
| Packaging | Approved configuration, test report, payload limits, conditioning instructions, assembly controls and change history | A quoted hold time with no tested configuration or acceptance criteria |
| Monitoring | Device specification, calibration, placement rationale, data-access rule, alarm workflow and review record | A device brand name without an operating procedure |
| People | Role-based training, competency checks, refresher schedule and authorized decision makers | Generic training claims with no link to the actual task |
| Handoffs | Chain-of-custody record, scan events, seal control, acceptance checks and named escalation contacts | Unrecorded transfer to an unidentified subcontractor |
| Exceptions | Response times, quarantine, product-owner notification, raw data preservation, investigation and recovery plan | A promise to “resolve issues” without thresholds or decision authority |
IATA CEIV Pharma, for example, assesses a defined range of quality, training, documentation, infrastructure, equipment, monitoring, validation and operational topics for air-cargo participants. That is meaningful evidence for the assessed scope; it is not automatic proof for every legal entity, station, subcontractor, lane, product or packout. Verify the current certificate and scope, then complete the product- and lane-specific review.
7. Treat named companies as examples, not a ranking
The following examples illustrate different public service positions. They are not a “top companies” list, an endorsement or proof of suitability. Service availability and quality-system scope can vary by country, facility and lane, so confirm the current legal entity and operating details directly.
| Example | Officially described service position | What still requires verification |
|---|---|---|
| DHL Life Sciences & Healthcare | Integrated healthcare logistics across transport, warehousing and specialized service categories | Exact country, facility, lane, subcontractors, controlled range and qualification evidence |
| World Courier Clinical Trial Logistics | Clinical-trial supply services that include logistics, depot and patient- or site-oriented workflows | Protocol fit, country coverage, depot scope, custody, monitoring and exception process |
| Cryoport Advanced Therapy Shippers | Specialized shipper systems and services for advanced-therapy and cryogenic workflows | Product compatibility, equipment and lane scope, custody controls, replenishment and recovery |
Use the same evidence standard for a large global network, a regional specialist and a local operator. The brand determines whom you contact; the documented scope determines what you can approve.
8. Use an eight-step shortlist review
- Approve the product condition, payload range, route, service boundary and acceptance criteria.
- Choose the provider type or combination of providers that matches the use case.
- Map every site, mode, handoff, subcontractor and data owner on the proposed lane.
- Check the current legal entity, licences, certifications and audited scope for each critical operation.
- Review facility, equipment, packaging, monitoring, training and contingency evidence.
- Define responsibilities, communication windows, records, deviation handling and change notification in the quality agreement or controlled contract.
- Run any required lane assessment, packaging qualification, trial shipment or operational verification before routine release.
- Approve the service with performance review, audit rights, change control and a requalification trigger.
The Compliance Checklist Generator can turn the review into a working evidence list. The Packaging Selector can help organize packaging inputs, but neither tool approves a provider or a lane.
9. Watch for warning signs and control changes
- A global coverage claim with no site- or lane-level operating detail.
- A certification presented without its entity, location, service scope or current validity.
- A hold-time claim that omits the tested payload, conditioning method, ambient profile and acceptance criteria.
- Monitoring data that the shipper cannot access promptly or in raw form.
- Unidentified subcontractors or handoffs with no defined custody and escalation process.
- A service change that can be implemented without risk assessment or prior notification.
After approval, monitor more than on-time delivery. Review temperature events, alarm response, missing data, damaged or delayed shipments, packaging deviations, investigations, corrective actions and provider changes. A capable provider on the original lane can become an unsuitable provider after a facility, route, subcontractor, device, packout or procedure changes.
For the transport fundamentals behind these controls, see the cold-chain transport guide. For distribution-network controls after provider selection, use the pharmaceutical cold-chain distribution guide.
Frequently asked questions
What is a pharma cold chain logistics company?
It is a provider that performs one or more controlled logistics activities for temperature-sensitive pharmaceutical products, such as storage, packing, transport, clinical-trial distribution, monitoring or specialized cryogenic handling. The term does not mean every provider performs all of those activities, so its exact service scope must be defined.
Is GDP or CEIV Pharma certification enough to approve a provider?
No. A relevant, current certification can support due diligence for the entity, location and activities within its scope. Approval still requires product- and lane-specific review of sites, subcontractors, packaging, monitoring, handoffs, records, exception response and applicable regulatory requirements.
Which provider type fits clinical trials or cell and gene therapies?
Clinical trials may need protocol-controlled depots, kit distribution, returns and site or patient delivery. Cell and gene therapies may also require cryogenic systems, strict identity and custody controls, urgent recovery and specialized handling. Select a provider only after matching these requirements to documented operating capability on the exact countries and lanes involved.
What evidence should be reviewed before awarding a lane?
Review the lane map, quality-system and certification scope, facility and equipment qualification, training, approved packaging configuration, monitoring and calibration controls, handoff records, subcontractor oversight, contingency plan, deviation process and change-control terms. The required depth depends on product risk and the governing quality system.
Bottom line: the best pharma cold-chain provider is not the company with the longest service list. It is the operating model whose exact sites, lane, people, packaging, monitoring, handoffs and exception controls can be demonstrated for the shipment you need to protect.
